Overview
AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) is a large-scale, international cancer data-sharing initiative. Here's a quick overview:
What it is: A publicly accessible cancer registry of real-world clinico-genomic data assembled through data sharing between 20 leading international cancer centers.
Why it was created: No single institution is able to sequence and treat sufficient numbers of patients to improve clinical decision-making independently, so the AACR launched GENIE to pool data across institutions.
What data it contains: The registry aggregates, harmonizes, and links clinical-grade, next-generation cancer genomic sequencing data with clinical outcomes obtained during routine medical practice from nearly every cancer patient treated at these institutions. Ovarian and endometrial cancers are present, but make up less that 4% of the overall cohort.
Scale: As of its twelfth public data release, the registry had grown to more than 137,000 patients, with genomic and baseline clinical data from more than 153,000 tumors accessible through partners Sage Bionetworks and cBioPortal.
Goals: The project aims to enable precision cancer medicine research, including the identification of novel therapeutic targets, design of biomarker-driven clinical trials, and identification of genomic determinants of response to therapy.
Notes
Targeted panel only (300–500 genes; not WGS/WES). GENIE BPC ovarian sub-cohort provides richer clinical data for approved researchers.